SynDermix identifies and acquires the rights to innovative products, which it develops until a robust demonstration of their clinical value and then drives their commercialisation through corporate partnerships.
Created in late 2015 and funded by private investors, SynDermix operates a lean structure, which leverages the complementary expertise of a seasoned executive team and a broad network of selected service providers and key opinion leaders.
We value innovation, creativity, integrity, commitment and fairness. We believe that success is driven by good people drawn from a diverse range of talent and partners. We are driven by passion and professionalism.
Our focus is on products of natural origin that satisfy unmet healthcare needs and cosmetic demands.
This strategy enables us to benefit from accelerated timelines to market access — through orphan drug designation, or registration as a medical device or as a cosmetic product.
Our current portfolio is based on three proprietary technology platforms: plant lectins, nitric oxide and vibration therapies.
These provide a broad range of medical and cosmetic products with indications that include oral mucositis, diabetic foot ulcers, chronic rhinosinusitis, acne, atopic dermatitis, as well as skin ageing and mouth hygiene.
Our most advanced medical product is in late stage Phase II development for the treatment of oral mucositis, while our cosmetic product against skin ageing is expected to enter the market by the end of 2018.